Product details

With an ever growing market for cancer medication, there was a seemingly fierce competition among pharma giants in this sphere. The British pharma major AstraZeneca had of late shown ample promises as some of its experiments with certain specific cancer medications had produced encouraging results. Such developments reportedly made the company a strong contender to occupy the position of established players like Merck, which was the erstwhile authority in terms of medication for certain specific types of cancer. But the company also had scripted some failures in establishing the ultimate efficacy of its products based on some earlier trials. In such a scenario, could AstraZeneca supersede Merck by making its own mark especially with medications for small-cell lung cancer? What would be the likely challenges for the pharma major in its efforts to stay ahead in the fray? What would be the rivals' stronger scoring points, how would AstraZeneca thwart those challenges?